Tata Elxsi Limited reported total income of ₹3,941.40 crore for the financial year ended March 31, 2026, compared to ₹3,908.36 crore in the previous year. The profit after tax (PAT) for the year was ₹628.43 crore against ₹784.94 crore in the previous financial year. The basic earnings per share decreased to ₹100.89 from ₹126.03 in the previous year.

The Board of Directors has recommended a dividend of ₹75 per equity share of face value ₹10 each, representing a payout of 750%, for the financial year ended March 31, 2026. This dividend is subject to the approval of shareholders at the 37th Annual General Meeting (AGM) scheduled to be held on Wednesday, June 24, 2026, at 10:30 a.m. IST via Video Conferencing or Other Audio Visual Means. If approved, the dividend will be paid on or after June 30, 2026, subject to the deduction of tax at source.

The Company has fixed Wednesday, June 10, 2026, as the record date to determine the entitlement of members to the dividend. The Register of Members will remain closed from Thursday, June 11, 2026, to Wednesday, June 24, 2026 (both dates inclusive).

Financial Highlights for FY 2025-26

The announcement was made in compliance with Regulation 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE670A01012/fe78064f-8b47-4925-84a7-9b55763a7002.pdf

Tata Elxsi has launched AnaTel, an AI-native software development platform designed for healthcare and medical technology companies, to reduce development cycle times by up to 60%. Co-developed with OpenAna, the platform addresses rising regulatory expectations by embedding autonomous AI agents directly into engineering workflows. AnaTel made its debut at DeviceTalks Boston 2026 on May 27, 2026.

The platform targets operational challenges in medtech software teams, where regulatory bodies like the FDA and Europe's MDCG require rigorous lifecycle documentation and traceability. AnaTel operates across the full AI-Driven Software Delivery Lifecycle, generating code, documentation, test cases, and regulatory artifacts. It supports eSTAR-aligned submission preparation and is expected to reduce SaMD development timelines from eight weeks to 72 hours.

Platform Capabilities

AnaTel functions as a configurable AI software team, drawing on a Healthcare and Life Sciences expert agent fine-tuned for medtech regulatory and engineering contexts. Key features include:

• Autonomous AI agents embedded in engineering workflows
• Generation of regulatory-grade documentation and test cases
• Support for requirements traceability matrices and audit trails
• Reduction in change assessment timelines

Strategic Partnership

The platform was developed through STEP.UP, Tata Elxsi's co-innovation program for deep-tech companies. Tata Elxsi contributes design-led engineering and domain expertise, while OpenAna provides its platform of autonomous engineers.

Sreevatsa Sahasranaman, Senior Vice President and Head, Healthcare and Life Sciences, Tata Elxsi, stated that the platform accelerates regulatory-ready software engineering while keeping experts in control. Rajiv Sondhi, Chief Executive Officer of OpenAna, highlighted the partnership's focus on lifecycle traceability and safety in demanding domains.